Xap Therapeutics
Biotechnology Research
Campus, United Kingdom
34 employees
- Employees
- 34
- Contacts
- 1
- Emails
- 1
Xap Therapeutics Overview
- Headquarters
- Campus, United Kingdom
- Website
- www.xaptherapeutics.com
- Industry
- Biotechnology Research
- Employees
- 34
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About Xap Therapeutics
Xap Therapeutics, formerly known as Rockend Ltd, is a start-up biotechnology company which is developing an innovative, synthetic biology driven platform for cell therapeutics. Based in Cambridge, UK, the company was founded by a group of experienced biotech entrepreneurs with significant funding from well-known US/UK blue-chip VCs. Xap Therapeutics applies CRISPR technology to engineer iPSCs. These iPSCs form the basis of a universal cell platform producing a “chassis” cell, which we can further functionalise into cell therapies by expression of genetically engineered constructs. Our cell products will have the ability to process external cues via engineered receptors and to release various types of cargos upon activation. The ultimate aim is to create novel cell therapies with mechanisms of action that are beyond reach of current approaches, thus bringing a step change improvement in the treatment of serious disease, including autoimmunity and cancer. We are hiring across a range of R&D functions and are looking to build an exceptional team out of industry and academia. This is a unique career opportunity for talented people to join our growing team, and to contribute to the generation of this exciting synthetic cell therapy platform and future clinical products. You will enjoy a varied and rewarding role and a flexible and dynamic working environment which values innovation and teamwork.
Xap Therapeutics Contact Details
- People in AeroLeads
- 4
- With contact data
- 1
- Email contacts
- 1
- 25.0% coverage
Xap Therapeutics Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Matthew Foy | CEO of Avante Biocapital |
View
|
|
| Juan-Jose Guijarro-Leach | Head of Analytical Development at Xap | London, England, United Kingdom |
View
|
| Sandra Van Wetering | Chief Technology Officer Xap | Netherlands |
Email
|
| Celeste Pallant | Principal Scientist at Xap Therapeutics |
View
|
Employees by Management Level
Executive
2 profiles
VP / Head
1 profile
Senior / Lead
1 profile
Compare Similar Companies to Xap Therapeutics
Insmed Incorporated
Biotechnology Research
Bicycle Therapeutics
Biotechnology Research
Bit.Bio
Biotechnology Research
T-Therapeutics Ltd
Biotechnology Research
STORM Therapeutics Limited
Biotechnology Research
Mosaic TX
Biotechnology
Shift Bioscience
Biotechnology Research
Econic Biosciences
Biotechnology Research
Neobe Therapeutics
Biotechnology Research
Auxolytic
Biotechnology Research